http://www.sprycel-global.com/references.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/share-site.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/share-site-confirmation.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/sitemap.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/splitter.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/international/cml.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/cml/chronic-myeloid-leukaemia.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/cml/imatinib-resistance.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/cml/resistant-to-imatinib.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/cml/resistance-to-imatinib.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/cml/imatinib-resistant.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/cml/imatinib-intolerance.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/international/cml.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/managing/cml-adverse-events.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/therapy/dasatinib.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/trial/chronic-myeloid-leukaemia.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/trial/chronic-phase-cml.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/trial/cml-treatment.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/trial/dasatinib-dose.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/trial/dasatinib-safety.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/dosing/chronic-myeloid leukaemia-treatment.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/dosing/chronic-phase-cml.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/dosing/dasatinib.aspx 2009-09-10 monthly 0.8 http://www.sprycel-global.com/dasatinib/cml-treatment.aspx 2009-09-10 monthly 0.8